Selective review and commentary on emerging pharmacotherapies for opioid addiction
| Autor: | Walter Ling, Suzanne Nielsen, Min Zhao, Karen Miotto, Larissa J. Mooney, Matthew Torrington |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Drug Abuse (NIDA Only) implant buprenorphine medicine.drug_class Best practice Clinical Sciences Alternative medicine Review Pharmacology buprenorphine film Naltrexone 03 medical and health sciences 0302 clinical medicine Acquired immunodeficiency syndrome (AIDS) Opioid receptor Clinical Research lofexidine Naloxone medicine 030212 general & internal medicine Prescription Drug Abuse Intensive care medicine Pediatric business.industry Neurosciences Substance Abuse Pharmacology and Pharmaceutical Sciences medicine.disease buprenorphine probuphine 3. Good health Brain Disorders Lofexidine business naltrexone 030217 neurology & neurosurgery Buprenorphine medicine.drug |
| Zdroj: | Substance Abuse and Rehabilitation Substance abuse and rehabilitation, vol 2, iss 1 |
| ISSN: | 1179-8467 |
| Popis: | Pharmacotherapies for opioid addiction under active development in the US include lofexidine (primarily for managing withdrawal symptoms) and Probuphine®, a distinctive mode of delivering buprenorphine for six months, thus relieving patients, clinicians, and regulatory personnel from most concerns about diversion, misuse, and unintended exposure in children. In addition, two recently approved formulations of previously proven medications are in early phases of implementation. The sublingual film form of buprenorphine + naloxone (Suboxone®) provides a less divertible, more quickly administered, more child-proof version than the buprenorphine + naloxone sublingual tablet. The injectable depot form of naltrexone (Vivitrol®) ensures consistent opioid receptor blockade for one month between administrations, removing concerns about medication compliance. The clinical implications of these developments have attracted increasing attention from clinicians and policymakers in the US and around the world, especially given that human immunodeficiency virus/acquired immunodeficiency syndrome and other infectious diseases are recognized as companions to opioid addiction, commanding more efforts to reduce opioid addiction. While research and practice improvement efforts continue, reluctance to adopt new medications and procedures can be expected, especially considerations in the regulatory process and in the course of implementation. Best practices and improved outcomes will ultimately emerge from continued development efforts that reflect input from many quarters. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|